Long-term outcomes of COVID-19 convalescents: An 18.5-month longitudinal study in WuhanArticle Published on 2023-02-012023-07-11 Journal: International Journal of Infectious Diseases [Category] COVID19(2023년), [키워드] COVID-19 CT abnormalities Depression and anxiety longitudinal cohort Lung function Sequelae. [DOI] 10.1016/j.ijid.2022.12.008 PMC 바로가기
Identification of circulating microRNA profiles associated with pulmonary function and radiologic features in survivors of SARS-CoV-2-induced ARDSSARS-CoV-2에 의해 유발된 ARDS 생존자의 폐 기능 및 방사선학적 특징과 관련된 순환 microRNA 프로파일 식별Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 유전자 메커니즘, 임상, [키워드] acute respiratory distress syndrome Anti-inflammatory ARDS association carbon monoxide cell death Chest computed tomography circulating Coagulation Complete composed Computed tomography conducted correlated COVID-19 develop diffusing diffusing capacity distress enrichment analyses enrichment analysis evaluated Evidence evidence of feature Features Follow-up Gene ontology genomes hospital discharge hypoxia identification immune response infected patient infected patients KEGG KEGG pathway Kyoto lung Lung function median microRNA miR-126 miR-146 miR-146a-5p miR-21 miR-9 miRNA miRNA profiles miRNA profiling miRNA signature molecular molecular mechanism molecular mechanisms Pathogenesis pathophysiology pathway Patient patients predicted profile provided Pulmonary function radiologic radiological feature radiological features Random forest respiratory distress Respiratory distress syndrome RT-qPCR SARS-COV-2 infection secondary to sequelae severe COVID-19 severity survivor to define total severity score. Trial registration TSS vascularization viral infection was performed was used [DOI] 10.1080/22221751.2022.2081615 PMC 바로가기 [Article Type] Article
Efficacy and safety of Treamid in the rehabilitation of patients after COVID-19 pneumonia: a phase 2, randomized, double-blind, placebo-controlled trialArticle Published on 2022-11-032022-11-16 Journal: Journal of Translational Medicine [Category] 비임상, [키워드] 1:1 Administered administration adverse event age Analysis animal model Anti-inflammatory assigned baseline Borg change changes in Chronic diseases clinical trial clinically COVID COVID pneumonia COVID-19 defined Diagnosis discharged double-blind Dyspnea Effect effective Efficacy Endpoint enrolled evaluated female female gender FEV first symptom FVC impairment increase in indicated Infection initial LLC lung damage Lung fibrosis Lung function Lungs mMRC moderate NCT04527354 offer past medical history Patient patients pharmacological treatment Placebo placebo group placebo-controlled clinical trial placebo-controlled trial Post-COVID rehabilitation predicted Prevent Primary outcome proportion pulmonary dysfunction pulmonary fibrosis Pulmonary function questionnaire Randomized Randomly reduction in Registered rehabilitation risk factor Russia SARS-CoV-2 secondary shown significant decrease significant difference stratified Support Symptoms Tolerability Treamid. Treatment Trial was done women [DOI] 10.1186/s12967-022-03660-9 PMC 바로가기
Clinical outcomes and lung ultrasound findings in COVID-19 follow up: Calm comes after the storm?Research article Published on 2022-11-012022-10-05 Journal: Respiratory medicine and research [Category] COVID19(2023년), SARS, 바이오마커, [키워드] acute infection Admission age Altered clinical conducted COVID-19 CRP Descriptive analysis detect diagnosed Dyspnea female Follow-up greater Hospital admission hospital discharge IL-6 level lung Lung function Lung ultrasound LUS manifestation Manifestations outcome paO2/fiO2 parameter Patient performed Pneumonia Post-COVID Quality of life questionnaire radiological Result SARS-CoV2 Spain Symptom the mean the patient university variable [DOI] 10.1016/j.resmer.2022.100907 [Article Type] Research article
Mid-term pulmonary sequelae after hospitalisation for COVID-19: The French SISCOVID cohortResearch article Published on 2022-11-012022-10-05 Journal: Respiratory medicine and research [Category] 임상, [키워드] age Chest computed tomography clinical examination Clinical features Cohort complications consequence COVID-19 CT-scan described diffusing discharge Dyspnoea evaluated Follow-up French functional hospital discharge hospitalisation hospitalised ICU impairment Improved independent risk factor intensive care Invasive mechanical ventilation lung lung capacity Lung function mMRC multicentre nasal non-invasive ventilation observational study outcome Pathogenesis Patient Patient discharge Pneumonia Pulmonary function tests radiological Result sequelae severe COVID-19 significantly more therapeutic option ventilatory [DOI] 10.1016/j.resmer.2022.100933 [Article Type] Research article
Changes in Care during the COVID-19 Pandemic for People with Cystic FibrosisArticle Published on 2022-10-012022-11-16 Journal: Annals of the American Thoracic Society [Category] 변종, [키워드] 95% CI 95% confidence interval age Ambulatory care BMI body mass index calculated Care change changed changes in children coronavirus disease COVID-19 COVID-19 pandemic Cystic cystic fibrosis effective eligible enrolled expiratory FEV foundation Lung function no difference Paired t test pandemic predicted proportion pulmonary exacerbation Pulmonary function pulmonary function. registry risk severe disease the mean transitioned transmembrane Volume [DOI] 10.1513/AnnalsATS.202105-532OC PMC 바로가기
The impact of platelets on pulmonary microcirculation throughout COVID-19 and its persistent activating factorsArticle Published on 2022-09-282022-11-15 Journal: Frontiers in Immunology [Category] 치료제, [키워드] activate activating addition aggregation antiplatelet Blood coagulation factor complex convalescent COVID-19 COVID-19 patients disease severity disorders endothelial injury Factor Gas exchange hypercoagulability hypercoagulable hypercoagulable states Hypoxemia hypoxia immune cells impaired lung function impairment incidence Inflammation Inflammatory mediators inhibiting Intervention intrinsic involved Lung function manifestation marker microvesicle Microvesicles Mild Mortality Phosphatidylserine Platelet platelet activation Platelets promote PROTECT pulmonary permeability pulmonary vasculitis reactivity reducing resulting risk severe cases stages the disease therapy Thromboembolism thrombosis thrombosis. thrombotic event tissue Treatment vessel walls with COVID-19 [DOI] 10.3389/fimmu.2022.955654 PMC 바로가기
Scars of COVID-19: A bibliometric analysis of post-COVID-19 fibrosisArticle Published on 2022-09-202022-11-15 Journal: Frontiers in Public Health [Category] SARS, 치료기술, [키워드] acute injury Analysis analyzed article changed Cluster collected Comorbidities coronavirus 2 coronavirus disease country COVID-19 COVID-19 pandemic Cystic database Diagnosis early phase English enrolled Epidemiology etiology Evidence experiment fibrosis French hotspot hotspots and trends Imperial College London Increasing individual level Infection international cooperation intrinsic investigated journal Laboratory Lung function material novel Pathogenesis Patient professional promote public health threat Quality of life Research reversed Spread Therapies therapy Therapy. university University of Washington USA vaccination Volume was performed Web of Science [DOI] 10.3389/fpubh.2022.967829 PMC 바로가기
Differences in lung function between major race/ethnicity groups following hospitalization with COVID-19Research article Published on 2022-09-012022-10-05 Journal: Respiratory medicine [Category] 유전자 메커니즘, [키워드] age Americans average black Black patient BMI center Complete Corticosteroids COVID-19 death demonstrated difference diffusion capacity discharge domain FVC group Hispanic Hispanic patients Hospitalization Hospitalized ICU admission impairment independent Lung disease lung dysfunction Lung function lung volumes parameter Patient predicted prevalent Pulmonary function testing question questionnaire rates of infection respiratory symptom Result smoking status spirometry statistically significant statistically significant difference Treatment University of Virginia white with COVID-19 [DOI] 10.1016/j.rmed.2022.106939 [Article Type] Research article
Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients – the randomized, EU-wide, placebo-controlled, phase II study design of IXIONClinical Trial Published on 2022-08-192022-10-05 Journal: Trials [Category] SARS, 임상, [키워드] addition Administered Admission capillary Capillary leak Clinical management clinical study code coronavirus COVID-19 COVID-19 patient COVID-19 patients COVID-19 severity Deterioration disease Disease progression double-blinded drop-out Endothelial dysfunction Endpoint enrolled EudraCT Europe France FX06 Germany Hospital stay Hospitalization Hospitalized hospitalized patient Human ICU Inflammation. intravenously Italy lack limitation Lithuania Lung function mammals Mild moderate multicentre Non-intubated occurred outbreak oxygen saturation Patient patient recruitment patients patients receiving placebo peptide per day Placebo placebo-controlled Portugal positive SARS-CoV-2 PCR Potential Prevent prevent disease progression primary endpoint problem proportion protocol randomization Randomized receiving recruitment reduce Romania SARS-CoV-2 secondary Spain stages standard care Study design subject survival systemic inflammation the WHO therapy while [DOI] 10.1186/s13063-022-06609-x PMC 바로가기 [Article Type] Clinical Trial